What is Avitar Inc?
, through its subsidiaries, designs, develops, manufactures, and markets diagnostic test products and proprietary hydrophilic polyurethane foam disposables for medical, diagnostics, dental, and consumer applications in the United States.
AVTI · Verdict
Limited reward · moderate risk
AVTI stands out on volatility and balance sheet, but watch the profitability signal.
Based on 88% data coverage
AVTI · Verdict
Above average
Current ratio 0.14
Above average
-73% net margin · 0% ROE
Rev -8.5% CAGR · earnings -2.2%
-73% net margin
Model-based scoring. For information only — not financial advice.
, through its subsidiaries, designs, develops, manufactures, and markets diagnostic test products and proprietary hydrophilic polyurethane foam disposables for medical, diagnostics, dental, and consumer applications in the United States. It offers ORALscreen 4 and ORALscreen DRUGOMETER, the oral fluid-based onsite assay systems, for detecting drugs of abuse, such as opiates, including heroin, morphine, codeine, and synthetic opiates comprising oxycocone-oxycontin, percoset, and hydrocodone-vicodin; cocaine, such as crack; marijuana; and methamphetamines, including meth and ecstasy. The company is listed on the OTCCE in USA, operating in the Healthcare sector, with a market capitalisation of 20.56K.
The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.